Neurodegeneration: Difference between revisions

From The School of Biomedical Sciences Wiki
Jump to navigation Jump to search
← Older editNewer edit →
mNo edit summary
Nnjm2 (talk | contribs)
7,735 edits
No edit summary
Line 1: Line 1:
'''Neurodegeneration''' describes the loss of structure or function to nervous tissue<ref>Merriam-Webster. (n.d.). Medical Dictionary. Available: http://www.merriam-webster.com/medlineplus/neurodegeneration. Last accessed 09/11/2014.</ref>. Neurodegenerative diseases include&nbsp;[https://teaching.ncl.ac.uk/bms/wiki/index.php/Alzheimers_Disease Alzheimer’s], [https://teaching.ncl.ac.uk/bms/wiki/index.php/ALS ALS], [https://teaching.ncl.ac.uk/bms/wiki/index.php/Huntingtons_Disease Huntington’s] and [https://teaching.ncl.ac.uk/bms/wiki/index.php/Parkinsons_Disease Parkinson’s]<ref>Bredeson, D. (2006). Cell death in the nervous system. Nature, 796-802.</ref>.  
'''Neurodegeneration''' describes the loss of structure or function to nervous tissue<ref>Merriam-Webster. (n.d.). Medical Dictionary. Available: http://www.merriam-webster.com/medlineplus/neurodegeneration. Last accessed 09/11/2014.</ref>. Neurodegenerative diseases include&nbsp;[[Alzheimer's_disease|Alzheimer’s]], [[ALS|ALS]], [[Huntington’s_disease|Huntington’s]] and [[Parkinson’s|Parkinson’s]]<ref>Bredeson, D. (2006). Cell death in the nervous system. Nature, 796-802.</ref>.  


<span style="line-height: 1.5em;">Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where [https://teaching.ncl.ac.uk/bms/wiki/index.php/Protein_aggregation proteins aggregate] – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly<ref>Aguzzi, A., &amp;amp;amp;amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.</ref>. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation<ref>Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.</ref>.</span>  
<span style="line-height: 1.5em;">Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where [[proteins aggregate|proteins aggregate]] – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly<ref>Aguzzi, A., &amp;amp;amp;amp;amp;amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.</ref>. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation<ref>Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.</ref>.</span>  


<br>
=== References  ===


<span style="line-height: 1.5em;"><references /></span><br>
<span style="line-height: 1.5em;"><references /></span><br>

Revision as of 06:43, 11 November 2014

Neurodegeneration describes the loss of structure or function to nervous tissue[1]. Neurodegenerative diseases include Alzheimer’s, ALS, Huntington’s and Parkinson’s[2].

Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where proteins aggregate – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly[3]. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation[4].

References

  1. ↑ Merriam-Webster. (n.d.). Medical Dictionary. Available: http://www.merriam-webster.com/medlineplus/neurodegeneration. Last accessed 09/11/2014.
  2. ↑ Bredeson, D. (2006). Cell death in the nervous system. Nature, 796-802.
  3. ↑ Aguzzi, A., &amp;amp;amp;amp;amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.
  4. ↑ Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.


Retrieved from "https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Neurodegeneration&oldid=11610"